Additional file 1 of Assessing the impact of a national clinical guideline for the management of chronic pain on opioid prescribing rates: a controlled interrupted time series analysis
Creators: name: Hébert, Harry L.
name: Morales, Daniel R.
name: Torrance, Nicola
name: Smith, Blair H.
name: Colvin, Lesley A.
Publisher: name: figshare
Year: 2022
Subjects: subject: Medicine
subject: Cancer
subject: Science Policy
subject: 111714 Mental Health
subject: FOS: Health sciences

description: Additional file 1: Supplementary Box S1. Summary of the original SIGN 136 guideline (2013 edition) intervention for use of opioids in the management of adults with chronic non-malignant pain in non-specialist settings. Supplementary Box S2. Summary of the original SIGN 136 guideline (2013 edition) recommendations for use of gabapentinoids (gabapentin and pregabalin) in the management of adults with chronic non-malignant pain in non-specialist settings. Supplementary Table S1. Framework for Enhanced Reporting of Interrupted Time Series Studies (FERITS) Statement. Supplementary Table S2. List of opioids (BNF chapter 4.7.2), opioid-containing combination analgesics and gabapentinoid drugs included in the study and the number of items prescribed in Scotland between Q1 2005 and Q2 2020. Supplementary Table S3. Mid-year population estimates for Scotland. Supplementary Table S4. Mid-year population estimates for age and gender demographics in Scotland. Supplementary Table S5. Results of the controlled interrupted time series analysis of weak compared to strong opioid prescribing rates in Scotland. Supplementary Table S6. Results of the single interrupted time series analyses of female and male opioid prescribing rates in Scotland. Supplementary Table S7. Results of the controlled interrupted time series analysis of females compared to male opioid prescribing rates in Scotland. Supplementary Table S8. Results of the single interrupted time series analyses of opioid prescribing rates by age category in Scotland. Supplementary Table S9. Single-group interrupted time series analysis of opioids in Scotland (without buprenorphine, buprenorphine and naloxone and methadone hydrochloride). Supplementary Table S10. Results of the controlled interrupted time series analysis of opioid prescribing rates adjusted for gabapentinoid prescribing in Scotland (without buprenorphine, buprenorphine and naloxone and methadone hydrochloride). Supplementary Table S11. Results of the single interrupted time series analyses of female and male opioid prescribing rates in Scotland (without buprenorphine, buprenorphine and naloxone and methadone hydrochloride). Supplementary Table S12. Results of the controlled interrupted time series analysis of females compared to male opioid prescribing rates in Scotland (without buprenorphine, buprenorphine and naloxone and methadone hydrochloride). Supplementary Table S13. Results of the single interrupted time series analyses of opioid prescribing rates by age category in Scotland (without buprenorphine, buprenorphine and naloxone and methadone hydrochloride). Supplementary Table S14. Results of the single interrupted time series analyses of strong opioid prescribing rates in Scotland (without buprenorphine, buprenorphine and naloxone and methadone hydrochloride). Supplementary Table S15. Results of the controlled interrupted time series analysis of weak compared to strong opioid prescribing rates in Scotland (without buprenorphine, buprenorphine and naloxone and methadone hydrochloride). Supplementary Figure S1. Opioid prescribing time series across Scotland by gender, before and after the publication of SIGN 136 in December 2013. Supplementary Figure S2. Opioid prescribing time series across Scotland by age, before and after the publication of SIGN 136 in December 2013. Supplementary Figure S3. Opioid and gabapentinoid prescribing time series in Scotland (without opioid replacement therapies) before and after the publication of SIGN 136 in December 2013. Supplementary Figure S4. Prescribing time series of weak and strong opioids in Scotland (without opioid replacement therapies), before and after the publication of SIGN 136 in December 2013. Supplementary Figure S5. Opioid prescribing time series across Scotland by gender (without opioid replacement therapies), before and after the publication of SIGN 136 in December 2013. Supplementary Figure S6. Opioid prescribing time series across Scotland by age (without opioid replacement therapies), before and after the publication of SIGN 136 in December 2013.